Notice for gilteritinib (as fumarate) (Astellas Pharma Australia Pty Ltd)
Active ingredients
gilteritinib (as fumarate)
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Film-coated tablet
Indication
gilteritinib (as fumarate) is indicated for the treatment of adult patients who have relasped or refactory acute myeloid leukemia (AML) with a FLT3 mutation.
Therapeutic area
Haematology